MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-10-2022
PLx Pharma Total Shareholders Equity 2011-2026 | PLXP
Annual Total Shareholders Equity PLx Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 35.7 M | -10.9 M | -12.1 M | 6.44 M | 4.62 M | -2.32 M | 30.8 M | 25.9 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 35.7 M | -12.1 M | 9.77 M |
Quarterly Total Shareholders Equity PLx Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 10.2 M | 16.5 M | 26 M | 35.7 M | 30.9 M | 40.1 M | 44.7 M | -10.9 M | -10.9 M | -10.9 M | -10.9 M | -12.1 M | -12.1 M | -12.1 M | -12.1 M | 6.44 M | 6.44 M | 6.44 M | 6.44 M | 4.62 M | 4.62 M | 4.62 M | 4.62 M | -2.32 M | -2.32 M | -2.32 M | 15 M | 114 K | 30.8 M | 30.8 M | 30.8 M | 25.9 M | 25.9 M | 25.9 M | - | 3.21 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 44.7 M | -12.1 M | 9.65 M |
Total Shareholders Equity of other stocks in the Drug manufacturers industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-808 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.25 | -3.02 % | $ 134 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
14.8 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.01 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
557 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-6.6 B | - | - | $ 28.9 M |  Irlanda |
 |
OrganiGram Holdings
OGI
|
300 M | $ 1.74 | 0.29 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
263 M | $ 4.17 | -1.07 % | $ 549 M | USA |
 |
Emergent BioSolutions
EBS
|
649 M | $ 12.94 | -3.14 % | $ 663 M | USA |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
Athenex
ATNX
|
-6.51 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | $ 21.52 | 0.19 % | $ 2.05 B |  France |
 |
Sundial Growers
SNDL
|
270 M | $ 1.65 | 0.3 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 3.65 | -3.44 % | $ 4.53 M | USA |
 |
Evolus
EOLS
|
5.52 M | $ 5.61 | -2.35 % | $ 348 M | USA |
 |
Harrow Health
HROW
|
70.8 M | $ 47.21 | -7.51 % | $ 1.54 B | USA |
 |
China Pharma Holdings
CPHI
|
7.75 M | $ 1.29 | -4.79 % | $ 22.5 M |  China |
 |
Tilray
TLRY
|
3.32 B | $ 9.15 | 0.26 % | $ 5.65 B | Canada |
 |
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
-1.02 B | $ 7.47 | -3.93 % | $ 2.73 B | Canada |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
22.9 M | $ 4.78 | -1.04 % | $ 67.2 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | Canada |
 |
Veru
VERU
|
32.3 M | $ 2.35 | 1.73 % | $ 317 M | USA |
 |
Aurora Cannabis
ACB
|
2.13 B | $ 4.25 | -0.47 % | $ 86.3 M | Canada |
 |
Pacira BioSciences
PCRX
|
778 M | $ 23.67 | -9.03 % | $ 1.09 B | USA |
 |
PetIQ
PETQ
|
223 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
4.32 B | $ 14.99 | 1.94 % | $ 2.06 B | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
1.96 M | $ 1.08 | -0.46 % | $ 4.66 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
21.3 M | $ 0.94 | -3.6 % | $ 21.9 M | USA |
 |
Relmada Therapeutics
RLMD
|
85.4 M | $ 4.27 | -3.61 % | $ 129 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
138 M | $ 9.12 | -2.04 % | $ 648 M | USA |
 |
Solid Biosciences
SLDB
|
137 M | $ 5.25 | -1.22 % | $ 214 M | USA |
 |
SCYNEXIS
SCYX
|
73 M | $ 0.67 | 0.42 % | $ 32.1 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
29.3 M | $ 2.09 | 1.46 % | $ 21.8 M | USA |
 |
Viatris
VTRS
|
21.1 B | $ 12.74 | 1.07 % | $ 15.4 B | USA |
 |
Zomedica Corp.
ZOM
|
240 M | - | -0.21 % | $ 98 M | USA |